Climb Bio, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
CLYM$11.74+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balances at December 31, 2024 | 67,255,434 | $7 | $441,727 | $23 | $(229,876) | $211,881 |
| Vesting of restricted stock units | 320,333 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,022 | — | — | 2,022 |
| Unrealized gain on marketable securities | — | — | — | 263 | — | 263 |
| Net loss | — | — | — | — | (20,781) | (20,781) |
| Balances at March 31, 2025 | 67,575,767 | 7 | 443,749 | 286 | (250,657) | 193,385 |
| Vesting of restricted stock units | 188,333 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 1,013 | — | — | 1,013 |
| Unrealized gain on marketable securities | — | — | — | 32 | — | 32 |
| Net loss | — | — | — | — | (8,666) | (8,666) |
| Balances at June 30, 2025 | 67,764,100 | $7 | $444,762 | $318 | $(259,323) | $185,764 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balances at December 31, 2023 | 27,626,435 | $3 | $263,577 | $(2) | $(155,979) | $107,599 |
| Vesting of restricted stock awards and units | 24,579 | — | — | — | — | — |
| Issuance of common stock upon exercise of stock options | 10,999 | — | 15 | — | — | 15 |
| Stock-based compensation expense | — | — | 465 | — | — | 465 |
| Unrealized gain on marketable securities | — | — | — | 2 | — | 2 |
| Net loss | — | — | — | — | (1,697) | (1,697) |
| Balances at March 31, 2024 | 27,662,013 | 3 | 264,057 | — | (157,676) | 106,384 |
| Vesting of restricted stock awards and units | 32,453 | — | — | — | — | — |
| Issuance of common stock upon exercise of stock options | 2,248,504 | — | 8,652 | — | — | 8,652 |
| Stock-based compensation expense | — | — | 512 | — | — | 512 |
| Issuance of common stock in private placement, net of issuance cost of $250 | 31,238,282 | 3 | 119,747 | — | — | 119,750 |
| Issuance of common stock for the acquisition of in-process research and development from a related party | 5,560,047 | 1 | 41,867 | — | — | 41,868 |
| Net loss | — | — | — | — | (54,889) | (54,889) |
| Balances at June 30, 2024 | 66,741,299 | $7 | $434,835 | $— | $(212,565) | $222,277 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.